Welcome to our dedicated page for Aclarion news (Ticker: ACON), a resource for investors and traders seeking the latest updates and insights on Aclarion stock.
Aclarion, Inc. (NASDAQ: ACON) is a leading healthcare technology company specializing in the innovative use of Magnetic Resonance Spectroscopy (MRS) and proprietary biomarkers to optimize clinical treatments. Their flagship product, Nociscan, is a unique Software as a Service (SaaS) platform that noninvasively assists physicians in distinguishing between painful and nonpainful discs in the spine. By leveraging advanced MRS technology, Nociscan helps to identify the specific source of chronic low back pain (cLBP), a condition affecting 266 million people globally.
Nociscan generates reports based on MRS data collected from MRI machines, quantifying chemical biomarkers associated with disc pain. This data enables physicians to tailor treatment strategies optimally. The company derives its revenue primarily from the delivery of these Nociscan reports to medical professionals across the United States, enhancing their ability to make informed clinical decisions.
Recent developments highlight the company’s accelerated growth and significant milestones. Aclarion recently completed its 1,000th commercial Nociscan exam, marking an exciting phase of adoption. Moreover, the company is expanding Nociscan's compatibility beyond Siemens MRI machines, increasing its accessibility worldwide. The strategic partnership with Alphatec Spine, Inc. aims to integrate Nociscan into ATEC's AlphaInformatiX platform, providing comprehensive data to improve surgical decision-making for spine surgery.
The company is also initiating the pivotal multicenter, prospective, randomized CLARITY trial to validate superior surgical outcomes when Nociscan is integrated into surgical decision processes. Furthermore, Aclarion’s involvement in the LIFEHAB Trial in Norway underscores its commitment to advancing scientific understanding of chronic low back pain and improving patient outcomes.
Aclarion’s innovative approach is well-supported by a robust patent portfolio, including 22 U.S. patents and numerous international patents. The company's mission is to set a new standard of care in spinal diagnostics by offering noninvasive, data-driven insights that enhance the effectiveness of low back pain treatments.
Aclarion, Inc. (NASDAQ:ACON, ACONW), a healthcare technology firm, is set to present at the Third Annual Winter Wonderland - Best Ideas Virtual Investor Conference from February 21-24, 2023. Jeff Thramann, Executive Chairman, will present on February 21 at 11:30 AM ET. The conference will feature 37 top companies selected by qualified institutional investors. Aclarion leverages biomarkers and augmented intelligence to identify chronic low back pain and has developed Nociscan, a SaaS platform that helps physicians distinguish between painful and nonpainful discs. For more details, visit www.aclarion.com.
Aclarion, a healthcare tech company focusing on chronic low back pain (CLBP), announced its participation in the 2nd Annual Sonntag Spine Symposium on February 17, 2023. Aclarion's flagship product, Nociscan, is the first SaaS platform that objectively measures discogenic biomarkers to aid in diagnosing CLBP. This innovative tool helps distinguish between painful and nonpainful discs, providing critical insights for treatment strategies. With over 266 million people affected by generative spine disease globally, Nociscan aims to optimize clinical outcomes through enhanced decision support for physicians.
Aclarion, a healthcare technology company listed on Nasdaq under ACON and ACONW, has appointed Dr. Gregory Basil from the University of Miami as a key opinion leader. Dr. Basil, a renowned spine surgeon, aims to enhance clinical outcomes through Aclarion's innovative Nociscan platform, which identifies chronic low back pain sources via biomarkers. This SaaS solution allows physicians to differentiate between painful and nonpainful lumbar discs, offering critical insights for optimized treatment strategies. Dr. Basil is the seventh advisor to join Aclarion's clinical evidence team, reinforcing its commitment to improving patient care.
Aclarion, Inc. (Nasdaq: ACON, ACONW) has appointed George Frey, MD, as a key opinion leader to guide its innovative Nociscan solution for chronic low back pain (cLBP). Dr. Frey, founder of the Colorado Comprehensive Spine Institute, has extensive experience in medical device invention and patents. Aclarion's Nociscan platform uses biomarkers and algorithms to identify painful lumbar discs, addressing a major healthcare challenge. As cLBP significantly contributes to opioid addiction and healthcare costs, the company's advancements offer a new approach. Aclarion aims to leverage Dr. Frey's expertise to enhance its strategy and expand its KOL program into 2023.
Aclarion, a healthcare technology company, has appointed Dr. Christopher Ames as a Key Opinion Leader to enhance its Nociscan solution for chronic low back pain (cLBP). This SaaS platform is the first evidence-supported tool that helps physicians differentiate between painful and nonpainful discs in the lumbar spine. Dr. Ames emphasizes that the Nociscan tool will improve diagnostic clarity and patient outcomes. Additionally, Aclarion's Nociscan is included in a pivotal NIH-funded trial and has recently secured a new patent addressing painful disc degeneration.
Aclarion, a healthcare technology company, has appointed Dr. Eric Potts as a key opinion leader. Dr. Potts, a neurosurgeon, will assist in promoting Aclarion's Nociscan solution, which helps physicians identify chronic low back pain. Nociscan is the first SaaS platform to noninvasively distinguish between painful and nonpainful discs, leveraging chemical biomarkers. Aclarion aims to strengthen its clinical evidence and market support for this innovative approach, enhancing treatment strategies while addressing a major healthcare issue.
Aclarion, Inc. (ACON, ACONW) announced the appointment of Dr. Juan Uribe as a key opinion leader to enhance its efforts in chronic low back pain (cLBP) diagnostics. Dr. Uribe, renowned in spinal disorder research, will support Aclarion's objective of integrating clinical evidence and securing payer advocacy. The company's flagship Nociscan platform noninvasively identifies painful versus nonpainful lumbar discs using advanced biomarkers and algorithms. Aclarion aims to improve diagnostic accuracy and treatment strategies for cLBP, a leading cause of opioid addiction in the U.S.
Aclarion, Inc. (Nasdaq: ACON) has received a Notice of Allowance for its US Patent Application 16/224,590, enhancing its patent portfolio to 22 U.S. patents. This patent allows Aclarion to utilize Magnetic Resonance Spectroscopy (MRS) to identify Propionic Acid, a biomarker linked to bacterial infections in intervertebral discs. The Nociscan platform aids physicians in distinguishing between painful and nonpainful discs, potentially reducing unnecessary surgeries. CEO Brent Ness emphasized the importance of this advancement in supporting optimal treatment decisions for chronic low back pain.
Aclarion, Inc. (NASDAQ:ACON, ACONW), a healthcare technology company, presented at the 15th annual LD Micro Main Event on October 25, 2022. Executive Chairman Jeff Thramann delivered a company overview and business update. Aclarion focuses on chronic low back pain through its Nociscan platform, utilizing biomarkers and augmented intelligence to aid physicians in identifying pain sources in the lumbar spine. An updated investor presentation is available on their website, enhancing investor communications.
Aclarion, a healthcare technology company, has announced that Dr. Sigurd Berven will join as a key opinion leader to enhance the company's efforts in chronic low back pain diagnosis. Aclarion's Nociscan platform uniquely identifies painful discs using biomarkers and augmented intelligence. This technology aims to improve diagnostic accuracy and treatment strategies. Recently included in a NIH-funded trial, Nociscan further establishes its significance in the spine industry. Aclarion's focus is on robust clinical evidence and payer engagement to drive the adoption of its innovative solutions.
FAQ
What is the current stock price of Aclarion (ACON)?
What is the market cap of Aclarion (ACON)?
What does Aclarion, Inc. do?
What is Nociscan?
How does Aclarion generate revenue?
What recent achievements has Aclarion made?
What is the CLARITY trial?
What partnerships has Aclarion formed?
What is the significance of Nociscan's compatibility with different MRI machines?
What is the LIFEHAB trial?
How does Nociscan improve surgical outcomes?
What is Aclarion's patent portfolio like?
